Company / Return on Equity (ROE)
Akebia Therapeutics, Inc. Return on Equity (ROE) History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-16.4%
FY2025
5-year range
-1801.6% / -16.4%
FY2021-FY2025
Trend
-
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Akebia Therapeutics, Inc. reports negative total equity of -16.4% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-16.4% in FY2025 with a 5-year CAGR of +6.2%.
Improved from -70.8% to -16.4% over the past 4 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +1785.3pp
- 5-Year Change
- +6.2pp
- 10-Year Change
- -
Key checks
Key Insights
- Lowest return on equity (roe) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -16.4% | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | -1801.6% | -2443.3% |
| FY2021 | -70.8% | -213.7% |
| FY2020 | -22.6% | +62.4% |
| FY2019 | -60.1% | +69.8% |
| FY2018 | -199.3% | - |
| FY2015 | - | - |
| FY2014 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026